Palmitoylethanolamide (PEA)

CAM (antiinflammatory, modulating stress hormones in the HPA axis, influencing serotonin and dopamine)

  • Major Depression3
  • Migraines
  • Chronic Pain
  • Mania/mixed3
  • Long-COVID3
  • Autism3
  • Schizophrenia (negative symptoms)3

Features

, , , , , ,
Handout

Dosing

600 mg twice a day (can take 2 at night).

Management

This is not very effective for mania, but is natural and well tolerated.

EMR Text

Depression

Palmitoylethanolamide (PEA) use based on controlled trial in major depressive disorder (Ghazizadeh-Hashemi M et al, J Affect Disord. 2018;232:127-133).

Side effects of palmitoylethanolamide reviewed with patient.

Mania

Palmitoylethanolamide (PEA) use based on a randomized controlled trial in bipolar mania (Abedini T et al, Psychiatry Clin Neurosci 2022;76(10):505-511).

Side effects of palmitoylethanolamide reviewed with patient.

Autism

Palmitoylethanolamide (PEA) use based on a randomzied controlled trial in autism where it improved irritability and hyperactivity (Khalaj M et al, J Psychiatr Res. 2018;103:104-111)

Side effects of palmitoylethanolamide reviewed with patient.

Schizophrenia negative symptoms

Palmitoylethanolamide (PEA) use based on a randomzied controlled trial where it improved negative symptoms of schizophrenia (Salehi A et al, Psychiatry Res. 2022;316:114737).

Side effects of palmitoylethanolamide reviewed with patient.

Long COVID

Palmitoylethanolamide (PEA) use based on several randomzied controlled trials of long COVID where it improved olfaction, cognition, and energy (Ghazizadeh-Hashemi M et al, J Affect Disord 2018 ;232:127-133).

Side effects of palmitoylethanolamide reviewed with patient.

Search Treatments

Scroll to Top